Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China's National Medical Products Administration has approved Eli Lilly’s weight-loss pill, orforglipron, marketed as Foundayo. This once-daily pill is now the country’s first available oral GLP-1 treatment for obesity, cleared for chronic weight management by obese or overweight adults, as global drug makers pursue China's weight-management market.
Eli Lilly's Foundayo marks a significant regulatory first in China: the country's inaugural approved oral GLP-1 treatment for chronic weight management. GLP-1 medications mimic a natural gut hormone to help regulate appetite and metabolism. The approval by China's National Medical Products Administration positions Eli Lilly to address the needs of obese or overweight adults.
The introduction of an *oral* GLP-1 treatment is a notable development. While the provided information does not detail other GLP-1 options in China, an oral formulation like Foundayo's once-daily pill generally offers greater convenience for patients compared to injectable forms. This ease of administration could influence patient adoption and expand access to such treatments across China.
This approval allows Eli Lilly to enter China's weight-management market, which global pharmaceutical companies are actively targeting. However, the available details do not include information on the drug's pricing, its efficacy profile, or how its cost-effectiveness and safety compare to any non-oral alternatives that might be available or in development within China. These commercial and clinical factors will likely shape its market trajectory.
Share this article
Related reading
6 stories
Vietnamese Travellers Can Now Scan NETS QR Codes to Pay in Singapore

Saudi Wallet barq Signs MOU With TenPay Global for China Payments

Weixin Pay Sees 84% Rise in Overseas E-Wallet Transactions

BPC Pairs SmartVista with Huawei for Payment Modernisation

